Synopsis of recent research by authors named "Quinlan Wylie"
- Quinlan Wylie's research focuses primarily on the efficacy of targeted therapies, particularly trastuzumab (Herceptin®), in treating HER2-positive early breast cancer (EBC), highlighting its impact on overall survival compared to traditional chemotherapy methods.
- Wylie's systematic reviews and meta-analyses encompass extensive research strategies, analyzing data from randomized controlled trials and non-randomized studies to consolidate findings on HER2-targeted treatment outcomes over time.
- Apart from oncology, Wylie also investigates the molecular mechanisms underlying genetic disorders, such as SIFD, showcasing the effects of mutations on cellular respiration and the role of specific proteins in disease pathophysiology.
